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Abstract 
Background: Chronic thromboembolic pulmonary hypertension (CTEPH) 
results from incomplete resolution of pulmonary emboli. Pulmonary 
endarterectomy (PEA) is potentially curative, but residual PH following 
surgery is common and its impact on long-term outcome is poorly understood. 
We wanted to identify factors correlated with poor long-term outcome after 
surgery and specifically define clinically relevant residual PH post-PEA.  
 
Methods and Results: 880 consecutive patients (mean age 57 years) 
underwent PEA for CTEPH. Patients routinely underwent detailed re-
assessment with right heart catheterisation and non-invasive testing at 3-6 
months and annually thereafter with discharge if clinically stable at 3-5 years 
and not requiring pulmonary vasodilator therapy.  Cox regressions were used 
for survival (time-to-event) analyses. Overall survival was 86%, 84%, 79% 
and 72% at 1, 3, 5 and 10 years for the whole cohort and 91% and 90% at 1 
and 3 years for the recent half of the cohort. The majority of patient deaths 
after the peri-operative period were not due to right ventricular failure 
(CTEPH). At reassessment a mean pulmonary artery pressure (mPAP)  30 
mmHg correlated with pulmonary vasodilator therapy initiation post-PEA. An 
mPAP  38 mmHg and pulmonary vascular resistance  425 dyne/sec/cm-5 at 
reassessment correlated with worse long-term survival.  
 
Conclusions: Our data confirm excellent long-term survival and maintenance 
of good functional status post-PEA. Haemodynamic assessment 3-6 and/or 
12 months post-PEA allows stratification of patients at higher risk of dying 
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from CTEPH and identifies a level of residual pulmonary hypertension which 
may guide the long-term management of patients post-surgery.    
 
 
Key Words: Pulmonary Hypertension, pulmonary endarterectomy, pulmonary 
embolism, survival 
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Background 
Chronic thromboembolic pulmonary hypertension (CTEPH) is a complication 
of acute pulmonary emboli (PE) with uncertain prevalence, ranging from 0.57 
to 9.1%.1 The diagnosis is strongly associated with a history of acute venous 
thromboembolism.2 CTEPH results from incomplete resolution of PE which 
become organised into vessel walls and cause different degrees of 
obstruction to pulmonary blood flow. Increased pulmonary vascular resistance 
(PVR) leads to increased right ventricular pressure load and eventually to 
right ventricular failure. Historically the long-term outlook was poor with 5-year 
survival rates as low as 10%.3 Pulmonary endarterectomy (PEA) is the 
treatment of choice and in selected patients is curative.4 It is recognised that 
there is a steep surgical and institutional learning curve at the start of a PEA 
program, but in experienced centres the operative mortality rate is less than 
5%.5-7 A number of reports have confirmed improved short-term outcome in 
terms of haemodynamics, right ventricular function, quality of life, functional 
status and exercise capacity after surgery.7-18 Fewer reports describe long-
term outcome post-PEA and those that have been published are mainly 
retrospective and either only had small numbers of patients 19-26 or limited 
information of factors correlated with long-term outcome. 6, 27-31  
 
CTEPH is described by a two compartmental model with proximal vessel 
obstruction that is surgically accessible and a small vessel arteriopathy found 
in non-obstructed vessels, which is histologically similar to pulmonary arterial 
hypertension (PAH) and cannot be removed by surgery. 32, 33 This model 
explains why residual pulmonary hypertension (PH) can occur despite an 
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apparently successful surgical clearance. Depending on the definition used, 
between 11% and 35% of patients have residual PH following PEA.14, 25, 28-30 
Evidence suggests that long-term outcomes are dependent on post-operative 
haemodynamics. 6, 7, 12, 17, 23, 34 Persistently increased PVR greater than 500 
dyne/sec/cm-5 at the end of intensive care unit (ICU) stay is a significant risk 
factor for in-hospital death and mortality during the first year post-PEA. 6, 7, 12, 
34 PVR measured between 3 and 12 months after PEA can predict longer-
term outcome. 17, 23 In contrast, patients found to have a mean pulmonary 
artery pressure (mPAP) greater than 30 mmHg at follow-up had a smaller 
increase in exercise capacity, but no difference in survival at 4 years when 
compared to patients with an mPAP less than 30 mmHg after surgery. 29 In 
addition, a recent trial has shown an improvement in exercise capacity in 
patients with CTEPH that are inoperable or have persistent PH post PEA 35 
therefore further information on the natural history of disease would be helpful 
in identifying a low risk group who might not require drug therapy.  
 
The understanding of post-PEA haemodynamics and the consequences for 
patient management is thus incomplete. There is no consensus on the 
definition of residual (i.e. PH immediately after surgery or at early post-
operative follow-up when the remodelling of right ventricle is completed) or 
recurrent PH (i.e. when there is no PH on first assessment but then PH is 
identified subsequently). We present prospectively obtained long-term data 
from the United Kingdom (UK) national PEA cohort to identify the factors 
correlated with worse long-term outcome and specifically define what is 
clinically relevant PH, both residual and recurrent, after PEA.  
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Methods 
 
Study design 
 
Eight designated PH specialist centres from the UK and Mater Misericordiae 
University Hospital, Dublin, Ireland undertake the diagnosis and management 
of all CTEPH patients in these countries. All CTEPH patients are referred for 
consideration of PEA. Of importance, only designated PH centres can 
prescribe pulmonary vasodilator therapies. This system of care provides a 
unique opportunity to study the natural history of the disease following 
surgical intervention through the careful follow-up of a national cohort of all 
CTEPH patients. All data were entered prospectively into dedicated 
databases at Papworth Hospital and the other UK and Ireland specialist PH 
centres. This study was designed and conducted to describe current care 
therefore formal ethics approval was not required. The National Health 
Service (NHS) Health Research Authority Confidentiality Group was fully 
informed regarding the use of patient data. 
 
Patient selection 
Patient selection was as previously described.29 Consecutive patients who 
underwent PEA at Papworth Hospital from the first operation in January 1997 
until December 31st 2012 were included in this study with the exception of 
patients with chronic thromboembolic disease without PH (mPAP < 25 mmHg) 
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36 and those with conditions mimicking CTEPH e.g. pulmonary artery vasculitis 
or sarcoma.  
 
 
Surgical Technique 
 
PEA was performed using principles similar to those used by the University of 
California, San Diego group. 6, 34 All patients underwent surgical intervention 
with deep hypothermia, but complete arrest of the circulation was not used in 
all cases. 37, 38 Surgical specimens were classified into four types according to 
the Jamieson classification.39 Patients continued lifelong anticoagulation after 
surgery.  
 
Clinical assessment after surgery and long term follow up  
 
Pulmonary haemodynamics were recorded at 7 am on the first day after 
surgery and were routinely monitored until patients were extubated. At the 
start of the program, in those who had poor pre-operative haemodynamics 
and were in World Health Organisation (WHO) functional class III and IV, the 
decision to continue ‘bridging’ pulmonary vasodilator therapy was made on 
reviewing the ICU haemodynamics. With institutional experience, 'bridging' 
treatment is routinely stopped at the time of the surgery unless the pre-
operative haemodynamics were poor and there had been an unsatisfactory 
surgical clearance. Patients were followed up at Papworth Hospital at 3-6 and 
12 months post-PEA as previously described.29 Following their 12-month 
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post-PEA review patients were solely followed up by their referring PH centre. 
These teams managed the patients according to international guidelines 
including the need for additional right heart catheterisation (RHC) depending 
on clinical status and non-invasive tests. They also initiated pulmonary 
vasodilator therapy according to the UK national PH treatment guidelines, 
which allow off-license treatment of CTEPH patients in functional class (FC) II 
(only as part of a clinical trial), III or IV.  Patients were usually discharged from 
PH specialist centre follow-up after 5 years if the patient had good surgical 
clearance, remained in good FC (I or II) and did not require pulmonary 
vasodilator therapy. 
 
Long term survival assessment 
 
Survival after discharge from hospital was calculated using a censoring date 
of last review, transplant (n=1) or 11th September 2013, whichever was latest. 
The NHS summary care record tracking system was used for survival status 
(searched 11th September 2013).  The causes of death were obtained from 
local databases and from the England or Scotland General Register Offices. 
The causes of death were independently classified into four groups by three 
independent adjudicators (JEC, MT & JPZ). Discrepancies in the classification 
of death were discussed by the adjudicators to reach a consensus. The four 
groups were: 1) Post-operative death i.e. related to surgery e.g. reperfusion 
pulmonary oedema, multi-organ failure; 2) Death caused by CTEPH (CTEPH 
direct) i.e. right ventricular failure away from the operative period; 3) Death 
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related to CTEPH management (CTEPH related) e.g. due to anticoagulation 
and 4) Unrelated to CTEPH e.g. malignancy. 
 
Statistical analysis 
 
Statistical analyses were carried out using SAS (version 9.3, SAS institute, 
Cary, NC) and R (http://cran.r-project.org). Summary statistics (mean ± 
standard deviation) were calculated and paired t-tests and Wilcoxon signed 
rank sum tests performed to test the differences in baseline and post-surgery 
(3-6 months) patient characteristics. Kaplan-Meier curves were created for 
overall survival by cohort and treatment initiation. Cumulative incidence 
functions of cause-specific mortality were estimated taking competing risks 
into account. 40  
 
Cox regression methods were used to analyse the time to treatment initiation 
after PEA and the survival time after hospital discharge (all causes). The time 
scale was the time since PEA surgery. Due to left truncation at hospital 
discharge for long-term survival analysis, the hospital length of stay was 
adjusted for in Cox models. Further haemodynamic, FC and six-minute walk 
distance (6MWD) measured at follow-up visits were included as time-varying 
covariates in Cox regression models to examine their temporal associations 
with time to treatment initiation and long-term survival. Proportional hazard 
assumptions were checked by Schoenfeld residuals in univariable analyses. 41 
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To facilitate interpretations, we chose the best threshold values for mPAP, 
PVR and cardiac index (at follow-up visits) based on the largest likelihood 
ratio test statistics obtained in separate Cox regressions for time to treatment 
initiation (with other factors adjusted for, see Figure 2 legend) and CTEPH-
direct deaths after hospital discharge (no adjustment was made due to the 
smaller number of CTEPH-direct deaths observed). 42 In addition, graphical 
diagnostics on the functional forms of the relationships between log hazard 
ratios and mPAP, cardiac index and PVR were performed to evaluate the 
plausibility of the chosen best threshold values. Results of these categorized 
mPAP, PVR and cardiac index (based on best threshold values and clinical 
meaningful threshold values) were presented in the univariable and 
multivariable Cox regression analyses for long-term survival.    
 
 
Results 
 
Study cohort 
 
From 1997, until the end of 2012, a total of 880 consecutive patients with 
CTEPH underwent PEA at Papworth Hospital. The mean age was 57  15 
years (range 15-84) and 53% were male. The mean baseline mPAP was 47  
11 mmHg, PVR 830  382 dyne/sec/cm-5 and 6MWD 260  126 m. Pre-
surgery, 91% patients were in FC III or IV and 64% patients were taking at 
least 1 pulmonary vasodilator therapy as a "bridge to surgery" (Table 1). 
There was a history of malignancy or myeloproliferative disorder in 12.8%, 
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antiphospholipid syndrome in 4.3%, and splenectomy in 2.8% of patients at 
time of surgery (Table S1). There were significant improvements in 
haemodynamic variables, FC and exercise capacity post-surgery (Table 1). 
Despite this, only 28% of patients had an mPAP  20 mmHg, while 21% had 
mPAP 21-24 mmHg and 51% had mPAP  25 mmHg at the 3-6 month 
review. The mean follow-up of patients post-PEA was 4.3  3.6 years (range 
0-15.5 years). 
 
Initiation of pulmonary vasodilator therapy during long-term follow up  
 
Post-PEA, 187 patients were treated with 1 or more pulmonary vasodilator 
therapies. Of these, 45 patients who were “bridged” continued therapy post-
PEA long-term, while 142 patients were initiated on therapy after surgery, with 
the majority being started as the result of the first post-PEA review (Fig. 1). In 
univariable Cox regressions a number of demographic, functional and 
haemodynamic factors correlated with increased risk of treatment initiation 
during follow-up (Table S2). In multivariable Cox regressions (Table 2), we re-
examined the associations of treatment initiation for significant factors 
identified by univariable analyses. The associations of functional and 
haemodynamic variables at referral for PEA and over time post-PEA with 
treatment initiation remained statistically significant (p-values <0.05 except for 
cardiac index (over time) with a borderline p-value of 0.067) in multivariable 
analyses (Table 2). Additional analyses using a binary outcome of mPAP≥25 
mmHg at the first reassessment after hospital discharge had similar findings 
to those from the analyses for time to treatment initiation (Tables S3 & S4). 
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The best threshold values for pulmonary vasodilator therapy initiation over 
long-term follow-up were identified for mPAP, cardiac index and PVR as being 
30 mmHg, 2.14 L/min/m2 and 318 dyne/sec/cm-5 respectively. However, the 
graphical evidence in Figure S2 indicates that there was a rapid increase in 
log hazard ratio for treatment initiation for mPAP between 25 to 30 mmHg and 
after 30 mmHg the log hazard ratio started to plateau. This data analysis 
suggests that 30 mmHg is a plausible threshold and therefore patients with an 
mPAP ≥ 30 mmHg were at risk of a deteriorating functional status, which 
triggered pulmonary vasodilator therapy initiation. We propose this value 
represents clinically significant PH post-PEA and that these patients need for 
close long-term follow-up. No apparent patterns were observed for cardiac 
index and PVR.  
 
Recurrent PH and pulmonary emboli during long-term observation 
period 
 
Only 5 out of whole observed cohort who had an mPAP < 25 mmHg at their 3-
6 month re-evaluation went onto develop PH (mPAP  25 mmHg), had a 
clinical deterioration and were started on pulmonary vasodilator therapy 
during follow-up (Table S5). Of these only 2 patients had recurrent CTEPH 
without other causes e.g. recurrent PE or different cause for PH. To 
investigate the frequency of recurrent thromboembolism as the cause of 
recurrent or worsening pulmonary hypertension, we undertook an additional 
sub-analysis of patients managed locally by Papworth Hospital in the long-
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term. Six out of 356 patients suffered recurrent PE. Of these, all had an 
inferior vena cava filter in-situ and four had underlying antiphospholipid 
syndrome.  
 
Survival 
 
There were 174 deaths during a mean follow-up period of 4.3  3.6 years. The 
survival rates at 1, 3, 5 and 10 years were 86%, 84%, 79% and 72% 
respectively for the entire cohort from 1997 (Figure 2a). 92/174 (53%) of all 
deaths were classified as post-operative (Table S6). The cumulative 
occurrence of 30-day mortality improved significantly over time from 13.2% 
(95% confidence interval (CI) = [10.2%, 16.3%]) for the first half of our cohort 
to 2.4% (95%CI=[0.1%, 4.8%]) for the latest part of our cohort of patients 
undergoing PEA (Figure 2b). The overall survival rates at 1 and 3 years after 
surgery for the second half of our cohort were 91% and 90%, respectively 
(Figure 2c). This is despite the proportion of patients found to have the more 
'distal' bilateral type 3 thromboembolic disease at the time of surgery 
increasing from 8% in 2003 to 19% in 2012.  
 
For those patients who survived surgery, but died during the follow-up period: 
29/82 (35%) of deaths were classified as directly caused by CTEPH, 13 (16%) 
were related to CTEPH and 40 (49%) were due to unrelated causes (Figure 
2d and Tables S6-8).  
 
Factors correlated with long-term survival 
 15 
 
We wanted to understand the post-operative factors correlated with long-term 
survival. We, like others, have used day 1 post-PEA haemodynamic data as 
an indicator of haemodynamic response from PEA. There was only a 
moderate correlation between the day 1 and 3-6 month post-PEA mPAP 
(r=0.53) and PVR (r=0.57) (Fig. S1 A & B), but a stronger association 
between the 3-6 and 12 month post-PEA mPAP (r=0.75) and PVR (r=0.79) 
(Figure S1C & D). The 3-6 month haemodynamic measurements were 
therefore used for further analyses.   
 
A number of demographic, functional, haemodynamic factors and co-
morbidities including malignancy and atrial arrhythmias were identified in 
univariable Cox regressions to be correlated with long-term survival (Figure 3 
and Table S9). In multivariable analyses (Table 3) we individually re-
examined the associations of long-term survival for the significant factors 
identified in univariable analyses after adjusting for other important factors 
(gender, age, baseline BMI, prior history of malignancy or myeloproliferative 
disorder and hospital length of stay). Post-operative pulmonary vasodilator 
therapy initiation, worse FC, shorter 6MWD, higher mPAP, right atrial 
pressure (RAP) and PVR, lower cardiac index remained negatively correlated 
with long-term survival in multivariable analyses. An mPAP  36 mmHg and a 
PVR  416 dyne/sec/cm-5 (as time-varying measures) were the optimal 
thresholds correlated with a higher risk of death from any cause whereas an 
mPAP  38 mmHg and a PVR  425 dyne/sec/cm-5 identified those patients at 
higher risk of death due to CTEPH. The graphical diagnostics (Figure S2) 
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confirmed the plausibility of mPAP  38 mmHg as the threshold as there was 
a rapid increase in log hazard ratio between 35-38 mmHg before the log 
hazard ratio plateaued.  
 
Discussion  
This is the largest prospective national cohort study describing long-term 
outcomes post-PEA using a planned invasive haemodynamic evaluation and 
systematic long-term follow-up.  Our study has a number of important 
messages: 1. risk stratification of patients using invasive haemodynamic 
measurements at 3-6 and/or 12 months post-PEA can guide which patients 
need close long-term follow-up to identify clinical deterioration and need for 
additional treatment; 2. the majority of deaths following the immediate post-
operative period were not due to right ventricular failure (CTEPH); 3. long-
term survival post-PEA is excellent and most patients maintain a good 
functional status.  It was previously described that PEA results in excellent 
long-term survival and our data confirms this despite an older or comparable 
age at the time of surgery in our cohort than other series. 4, 23, 31, 43 Despite 
significant functional improvement following surgery with 85% of patients in 
either FC I or II, only 28% of patients had an mPAP  20 mmHg while 51% 
had an mPAP  25 mmHg when measured by RHC at 3-6 months post-PEA. 
The majority of patients in our cohort maintained a good functional status in 
the long-term despite residual PH by definition. 
  
The role of post-PEA haemodynamics in long-term patient management  
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There is no consensus on the definition of clinically significant residual PH 
post-PEA. Different centres apply a different definition depending on the local 
patient pathway. Our planned, systematic invasive haemodynamic evaluation 
in all UK patients over the first year post-surgery contrasts with others who 
base their post-operative outcome assessment on haemodynamics obtained 
immediately after PEA, while the patient is in ICU. 6, 12 We only found a 
moderate correlation between the day 1 ICU haemodynamics and the 3-6 
month measurements. A much stronger correlation existed between the 3-6 
and 12-month measurements. In our unit, we only record the day 1 ICU 
haemodynamics as stable patients have their Swan-Ganz catheter removed 
soon after, preventing later routine measurements in all patients. In 
comparison the Vienna group (n=110) 23 showed post-operative 
haemodynamics measured 4 days (mean) post-PEA, when patients were off 
inotropes, were very similar to those assessed at 1 year post-PEA.  
 
Pulmonary vasodilator therapy for residual PH after PEA 
This is the first study to report on factors correlated with pulmonary 
vasodilator therapy initiation post-PEA. 187 patients in our cohort were treated 
with pulmonary vasodilator therapy during a mean follow-up period of 4.3 
years. The majority were started soon after their 3-6 or 12 month post-PEA 
evaluations. A number of factors were independently correlated with their 
initiation including worse FC and 6MWD and higher mPAP and RAP. Post-
operative transfer co-efficient of the lung for carbon monoxide (TLco) also 
negatively correlated with the need to start pulmonary vasodilator therapy.  
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An arbitrary mPAP threshold of 30 mmHg, based on historical survival data, 3, 
44 was previously used by our group to analyse conditional long-term survival. 
29 In the current study, we also propose clinically significant PH post-PEA as 
an mPAP  30mmHg. In contrast to our previous study, this threshold is the 
result of an analysis of systematic clinical and haemodynamic data collected 
during the long-term follow-up of our large cohort of consecutive patients. This 
discussion of post-operative haemodynamics is currently specifically relevant 
because the first licensed therapy for the treatment of residual/recurrent PH 
post-PEA, Riociguat, is now available. In the CHEST-1 trial, 28% of patients 
included had residual/recurrent PH after PEA. 35 Although the inclusion criteria 
included an mPAP  25 mmHg and PVR > 300 dyne/sec/cm-5 the mean 
haemodynamics for the subgroup of patients with recurrent/residual PH post-
PEA was 39 mmHg and PVR 595 dyne/sec/cm-5. 45 In our cohort 397 patients 
would have met the entry criteria for the CHEST-1 trial, but only 174 were 
treated off-licence with other pulmonary vasodilator therapy while the other 
223 patients have remained in a good FC (I or II) during careful follow up by 
specialist PH physicians. Our data suggest that patients tolerated these 
haemodynamics well without evidence of deterioration. Our data analysis 
suggested an mPAP  30 mmHg was a plausible threshold that identified 
patients in this study likely to be started on pulmonary vasodilator therapy due 
to clinical deterioration during long-term follow-up. Other haemodynamic 
variables including PVR and cardiac index could be used to define clinically 
significant PH post-PEA. The evidence from our data only suggests a likely 
change in log-hazard ratios for treatment initiation at an mPAP  30 mmHg 
(Figure S2). We therefore propose that an mPAP  30 mmHg represents 
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clinically significant residual PH post-PEA and should guide clinicians which 
patients need close long-term follow-up after surgery.   
 
Our approach to start pulmonary vasodilator therapy post-PEA was 
conservative due to the limited evidence of effectiveness in this group of 
patients during the study. Due to the observational nature of our study and 
lack of a control group we were unable to determine whether they had any 
effect on survival. Pulmonary vasodilator therapy initiation was however 
independently correlated with poorer long-term survival. Similar results have 
recently been reported from an international CTEPH registry. 31 A potential 
bias with the factors correlated with pulmonary vasodilator therapy initiation 
post-PEA is that there were no fixed initiation criteria. However, in the UK 
pulmonary vasodilator therapy prescribing in CTEPH is limited to patients in 
FC III or IV (unless the patient is enrolled in a clinical trial) according to the UK 
National PH prescribing policy. 
  
Residual/recurrent CTEPH 
Only 5 patients developed recurrent PH (mPAP  25 mmHg) during follow-up. 
There were only 2 patients who had true recurrent CTEPH without new 
thromboembolic disease or other cause for PH. These patients presented 9 
and 10 years post-surgery and in both patients there was evidence of ongoing 
mosaic changes seen on computed tomography at their first re-evaluation 
post-PEA. This would suggest an ongoing disease process involving distal 
pulmonary arteries, which we hypothesise, progressed over time leading to 
recurrent CTEPH. The length of time after surgery that these patients re-
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presented is important because our mean follow-up was 4.3 years and only 
81 patients had 10-year follow-up.  Therefore it will be important to continue 
close follow up of the 223 patients in our cohort with mild residual PH post-
PEA, who currently remain in FC I or II without pulmonary vasodilator therapy. 
 
Post-operative long-term mortality 
In our cohort over half of the deaths were due to recognised complications in 
the post-operative period, with the highest proportion in the early part of the 
series. The 30-day mortality rate in the latest part of our cohort was 2.4%, 
which is comparable with other expert centres around the world.5-7 The 
majority of patient deaths during long-term follow-up were from other 
conditions rather than progressive right ventricular failure (CTEPH direct 
deaths). Ideally it would have been better to investigate the combined factors 
correlated with CTEPH direct deaths rather than all-cause mortality after 
surviving the operative period, but due to the small numbers this was not 
possible.  
 
Independent variables negatively correlated with long-term survival included 
post-operative pulmonary vasodilator therapy, worse FC, higher mPAP, RAP 
and PVR and lower cardiac index. Our best-fit mPAP values of 36 mmHg for 
all-cause deaths and 38 mmHg for CTEPH direct deaths were similar to those 
reported in 2 smaller series where a post-operative mPAP of 34 mmHg and 
37 mmHg correlated with poorer long-term outcome. 19, 26 In comparison, 
Skoro-Sajer and colleagues 23 did not find post-operative mPAP to be 
correlated with poorer outcome, but this may be due to the small sample size 
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in their study. Like mPAP, PVR has been reported as critical for post-PEA 
outcome and different thresholds suggested. 7, 12, 19, 23 Patients with a PVR 
above 500 dyne/sec/cm-5 immediately post PEA have a poorer peri-operative 
and 1 year survival. 7, 12 In comparison, data from Vienna suggests a PVR > 
590 dyne/sec/cm-5 was correlated with poor longer-term outcome. 23 Our 
results show a slightly lower threshold with 416 dyne/sec/cm-5 for all cause 
mortality and 425 dyne/sec/cm-5 for CTEPH direct deaths.  
 
Strengths and limitations 
Our baseline and follow-up demographic and haemodynamic data are very 
similar to previously published retrospective and prospective series from both 
single and multicentres. 6, 7-31 This allows any conclusions from this current 
study to be transferrable to other centres outside the UK if the reassessment 
of patients post-PEA is similar. Our study has a number of strengths including 
the prospective data entry, a large sample size and careful systematic long-
term follow-up by specialist PH physicians at designated PH Centres. We 
were also able to confirm the exact cause of death for all but one patient who 
died overseas, by obtaining death certificates for all patients. This allowed the 
adjudication of the cause of death by three independent observers. Our study 
also has a number of limitations. Although the data were entered 
prospectively it was not 100% complete, particularly for the patients in the 
early part of the cohort. For classification of residual PH ideally it would also 
be important to know whether the surgical clearance was completed at 
surgery, but at present there is no consensus about how this should be 
defined. Residual PH could be due to purely a small vessel arteriopathy or 
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mixed residual proximal disease and arteriopathy. This could contribute to a 
better description and prediction of those patients who may do worse or 
respond differently to treatment. Another factor that may alter the threshold for 
starting pulmonary vasodilator therapy post-PEA may be how well the right 
ventricle has re-modelled post-PEA. Interestingly, cardiac index was not found 
to independently predict long-term outcome or initiation of the pulmonary 
vasodilator therapy by multivariable analyses. Additionally, the methods for 
assessing right ventricular function by echocardiography have changed 
significantly over the study period making data analysis difficult.  
 
Conclusion 
Long-term survival post-PEA is excellent and the majority of patient deaths 
after the operative period were not due to right ventricular failure (CTEPH). 
Our data allow clinicians to better understand the natural history of CTEPH 
post-PEA and provides a description of patients at higher risk of long-term 
post-operative morbidity and mortality. Haemodynamics obtained 3-6 and/or 
12 months after PEA allows stratification of patients at higher risk of dying 
from CTEPH and identifies a level of residual PH, which may help in the 
selection of patients who need to be monitored closely, and considered for 
other treatment options.  
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Tables 
 
 Pre-
operative 
Post-
operative 
p-value 
Age (years) 57  15   
Sex (Male: Female %) 53:47   
BMI kg/m2 28.7  6.3    
FC 1/2/3/4 % 0/9/68/23 38/47/15/0 < 0.0001* 
 mPAP (mmHg) 47  11 27  10 < 0.0001* 
PVR (dyne/sec/cm-5) 830  382 317  239 < 0.0001* 
6MWD (m) 260  126 353  118 < 0.0001* 
 TLco (% predicted) 67   
Pulmonary vasodilator therapy (%) 64   
Mechanical ventilation length of time 
median (meanSD) (days) 
1 (2.5  4)   
ICU length of stay median 
(meanSD) (days) 
3 (7  9)   
Hospital length of stay median 
(meanSD) (days) 
16 (20  14)   
 
Table 1. Baseline and post-surgery patient characteristics.  Baseline (n = 
880) and post-operative characteristics (n = 748). Post-operative results are 
from 3-6 month post-PEA review. Values are mean  standard deviation. FC - 
WHO functional class, mPAP - mean pulmonary artery pressure, PVR - 
pulmonary vascular resistance, 6MWD - six-minute walk distance, TLco - 
transfer co-efficient of the lung for carbon monoxide. * vs. pre-operative 
values from paired t-tests (mPAP, PVR, 6MWD) and Wilcoxon signed rank 
test (for difference between pre-operative and post-operative FC).  
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Variables 
Hazard 
Ratio  
95% CI 
 
p-value 
 
N* 
Functional class 
(baseline) 
1,2    
0.0002 
 
116 3 3.74 0.89 15.73 
4 7.77 1.80 33.54 
 
Six minute walk  (baseline) 
  
0.65 0.52 0.80 <.0001 101 
 
mPAP (baseline) 
Linear 
effect 
1.44 1.12 1.84  
0.0138 
 
113 
Quadratic 
effect 
0.86 0.74 0.99 
 
RAP (baseline) 
  
1.29 1.12 1.50 0.0007 103 
 
Cardiac index (baseline) 
  
0.79 0.67 0.94 0.0070 111 
 
PVR (baseline) 
Linear 
effect 
1.27 1.09 1.48 
0.0008 
 
112 
Quadratic 
effect 
0.90 0.84 0.96 
 
Functional class 
(over time) 
1    
<.0001 
 
 
2 3.94 1.73 8.97 95 
>=3 22.84 9.83 53.05  
 
Six minute walk (over time) 
  
0.52 0.40 0.68 <.0001 88 
 
mPAP (over 
time) 
Linear 
effect 
25.77 11.98 55.41  
<.0001 
 
92 
Quadratic 
effect 
0.52 0.41 0.67 
 
RAP (over time) 
  
1.84 1.48 2.27 <.0001 91 
 
Cardiac index (over time) 
  
0.81 0.65 1.02 0.067 92 
 
PVR (over time) 
Linear 
effect 
1.87 1.46 2.39 
<.0001 
 
92 
Quadratic 
effect 
0.75 0.69 0.83 
 
TLco (over time) 
  
0.44 0.33 0.60 0.0142 66 
Table 2 Multivariable analyses for factors correlated with treatment 
initiation. These were adjusted for the following factors: gender, age, 
baseline BMI, baseline history of atrial flutter or fibrillation or COPD, bridging 
 35 
treatment pre-surgery and intraoperative classification of disease. All 
continuous variables were standardized (cardiac index: x-2.5/0.5, mPAP: x-
25/10, PVR: x-250/200). Quadratic terms for continuous variables are 
included if the formal tests on non-linearity are significant at 5% level. *N is 
the number of events (pulmonary vasodilator therapy initiation) available for 
analyses. 
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Variables 
Hazard 
Ratio 
95% CI p-value 
N* 
 
Functional class (over 
time) 
1  <.0001 
 
 
 
52 
 
 
 
2 6.37 2.23 18.26 
>=3 12.88 4.11 40.41 
 
Six minute walk (over time)  0.48 0.35 0.68 <.0001 48 
 
mPAP (over time, continuous) 1.57 1.20 2.04 0.0008 49 
 
mPAP (over time, 
categorized) 
 
 
 
<25  0.0003** 
 
 
 
 
49 
 
 
 
 
[25,30) 0.60 0.22 1.65 
[30,38) 1.57 0.66 3.75 
38+ 3.85 1.87 7.92 
 
RAP (over time) 1.95 1.46 2.60 <.0001 49 
 
Cardiac index(over time, continuous) 0.82 0.61 1.12 0.2149 48 
 
Cardiac index 
(over time, categorized) 
<2.16  0.0246** 
 
 
48 
 >=2.16 0.51 0.28 0.92 
 
PVR (over time, continuous) 
 
1.62 1.29 2.03 <.0001 47 
 
PVR (over time, 
categorized) 
 
 
<250  <.0001** 
 
 
47 
 
 
[250,425) 0.62 0.24 1.61 
425+ 4.69 2.25 9.78 
 
TLco (over time) 0.71 0.43 1.15 0.1615 24 
 
Pulmonary vasodilator 
therapy initiated YES 
2.59 1.48 4.53 
0.0009 
68 
 
ECMO YES 2.91 0.97 8.69 0.0562 68 
Table 3 Multivariable analyses for long-term mortality. Factors were 
adjusted for gender, age, baseline BMI, prior history of malignancy or 
myeloproliferative disorder and hospital length of stay. All continuous 
variables were standardized (see Table 2 legend). *N is the number of events 
(death) available for analyses. ** These p-values are not corrected for bias 
induced by selecting the largest likelihood ratio test statistics and cannot be 
used for inference. 41
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Figures 
 
 
 
Figure 1. Cumulative incidence (%) of pulmonary vasodilator therapy 
initiation after pulmonary endarterectomy. Number of patients at risk of 
treatment initiation over follow-up as shown. 
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Figure 2 Survival and classification of causes of death for PEA cohort.  
a) Kaplan-Meier curve showing cohort survival. b) Cumulative incidence of 
post-operative deaths improves with centre experience. PEA number is 
consecutive PEA operations including indications other than CTEPH. N= 
number of PEA operations for CTEPH. c) Kaplan-Meier curve comparing 
survival of 1st vs. 2nd half of cohort. d) Cumulative incidence of causes of 
death (see methods for classification) for patients surviving post-operative 
period. The number of patients at risk over follow-up as shown bottom of a) 
and c).
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Figure 3. Variables correlated with long-term mortality by univariable 
analyses. All continuous variables were standardized (see Table 2 legend). 
 40 
Red circles/bars define significant factors (p<0.05) and blue the non-
significant factors. 
